SCHEMBL410347

SCHEMBL410347

Cc1cccc(/N=N/c2ccc(N(C)C)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 8/20 1.00
▸ RAB9A P51151 7/20 1.00
▸ KMT2A Q03164 7/20 1.00
▸ MEN1 O00255 6/20 1.00
▸ TDP1 Q9NUW8 4/20 1.00
▸ CASP3 P42574 3/20 1.00
▸ SENP8 Q96LD8 3/20 1.00
▸ SENP7 Q9BQF6 3/20 1.00
▸ SENP6 Q9GZR1 3/20 1.00
▸ NSD2 O96028 1/20 1.00
▸ ALDH1A1 P00352 5/20 0.66
▸ MAPK1 P28482 4/20 0.66
▸ TSHR P16473 4/20 0.66
▸ HSD17B10 Q99714 2/20 0.66
▸ CA12 O43570 2/20 0.58
▸ CA2 P00918 2/20 0.58
▸ CA9 Q16790 2/20 0.58
▸ ALPL P05186 1/20 0.49
▸ ALPI P09923 1/20 0.49
▸ ALPG P10696 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29539676 1.00 NPC1 (1.00) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL410348 1.00 NPC1 (1.00) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL26712504 0.82 NPC1 (0.69) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL30471681 0.82 NPC1 (0.69) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL10814151 0.82 NPC1 (0.69) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL30332449 0.82 MEN1 (0.67) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL30102207 0.82 MEN1 (0.67) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL11981455 0.82 MEN1 (0.67) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL1405327 0.82 MEN1 (0.67) NPC1RAB9AKMT2AMEN1TDP1
SCHEMBL1405329 0.82 MEN1 (0.67) NPC1RAB9AKMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1664334-B1 METHOD AND DEVICE FOR DETERMINING IF A PRODUCT IS IN CONDITION FOR USE OR CONSUMPTION CRYOLOG S A (FR) 2012-04-18 — — EP claimed
JP-4834547-B2 — — 2011-12-14 — — JP claimed
US-7960176-B2 Method and device for determining if a product is in condition for use or consumption CRYOLOG SA (FR) 2011-06-14 — — US claimed
US-7588878-B2 Inkless printing paper and method XEROX CORPORATION (US) 2009-09-15 — — US claimed
US-7553603-B2 Inkless printing paper and method XEROX CORPORATION (US) 2009-06-30 — — US claimed
US-20080311518-A1 INKLESS PRINTING PAPER AND METHOD XEROX CORPORATION (US) 2008-12-18 — — US claimed
US-20080311517-A1 INKLESS PRINTING PAPER AND METHOD XEROX CORPORATION (US) 2008-12-18 — — US claimed
EP-2003503-A1 Inkless printing paper and method Xerox Corporation (US) 2008-12-17 — — EP claimed
US-20070275467-A1 Method and Device for Determining if a Product is in Condition for Use or Consumption CRYOLOG S.A. (FR) 2007-11-29 — — US claimed
EP-1664334-A1 METHOD AND DEVICE FOR DETERMINING IF A PRODUCT IS IN CONDITION FOR USE OR CONSUMPTION Cryolog S.A. (FR) 2006-06-07 — — EP claimed
WO-2005026383-A1 METHOD AND DEVICE FOR DETERMINING IF A PRODUCT IS IN CONDITION FOR USE OR CONSUMPTION CRYOLOG S.A. (FR) 2005-03-24 — — WO claimed
US-20220202861-A1 TREATMENT OF LIVER FAILURE BY EX VIVO REPROGRAMMED IMMUNE CELLS CREATIVE MEDICAL TECHNOLOGIES, INC. (US) 2022-06-30 — — US disclosed
US-20210115489-A1 NOVEL MEDIATOR KIKKOMAN CORPORATION (JP) 2021-04-22 — — US disclosed
US-20200171088-A1 TREATMENT OF LIVER FAILURE WITH ACTIVATED T REGULATORY CELLS Viera Bioscience, Inc. 2020-06-04 — — US disclosed
EP-3616733-A1 EXTRACORPOREAL ARTIFICIAL LIVER, DEVICE FOR EXTRACORPOREAL ARTIFICIAL LIVER OR HEPATOCYTE CULTURE Yonemitsu, Yoshikazu (JP) 2020-03-04 — — EP disclosed
EP-0253325-A2 Oncogene-related peptides Yanaihara, Noboru (JP) 1988-01-20 — — EP disclosed
US-4678436-A Color-changeable cement composition for dental use G-C DENTAL INDUSTRIAL CORP. (JP) 1987-07-07 — — US disclosed
EP-0024202-B1 2,3,4,5,6-PENTA-O-ACETYL-D-GLUCONYL ISOTHIOCYANATE FOR USE IN PREVENTING AND TREATING CANCER NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1983-07-20 — — EP disclosed
US-4357349-A 2,3,4,5,6-PENTAACETYL GLUCONYL ISOTHIOCYANATE NITTO CHEMICAL INDUSTRY CO. (JP) 1982-11-02 — — US disclosed
EP-0024202-A1 2,3,4,5,6-Penta-O-acetyl-D-gluconyl isothiocyanate for use in preventing and treating cancer NITTO CHEMICAL INDUSTRY CO., LTD. (JP) 1981-02-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115489-A1 NOVEL MEDIATOR MPO, EPX, LPO NPC1 4474/4885RAB9A 3686/4885KMT2A 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback